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ABSTRACT
The Streptococcus agalactiae colonization prevalence and its susceptibility to antimicrobials in pregnant women at
University Hospital of Santa Maria (HUSM) were evaluated from June to December 2009. The vaginal-rectal material
was inoculated into tubes containing Todd-Hewitt broth with subsequent subculture on blood agar. The GBS
identification was made through presumptive tests, confirmed by serological test and its susceptibility was evaluated. The
occurrence ofGBS maternal-fetal transmission in the colonized pregnant women was researched. The GBS colonization
was 11 .11%. All strains were susceptible to penicillin, ampicillin, and vancomycin. Two strains (50%) were intermediate
to clindamycin and one (25%) intermediate to erythromycin. A newborn whose mother was colonized had early-onset
neonatal infection by GBS. By this, it is very important the research about the colonization by GBS in all pregnant
women from 35 to 37 weeks of gestation and the use of intrapartum antibiotic prophylaxis for colonized pregnant
women.
Descriptors: Streptococcus agalactiae; Prevalence; Pregnant women; Newborns; Microbial Sensitivity Tests.
RESUMO
Avaliou-se a prevalência de colonização pelo Streptococcus agalactiae e o seu perfil de sensibilidade frente aos
antimicrobianos em gestantes no Hospital Universitário de Santa Maria (HUSM), de junho a dezembro de 2009. O
material vaginal-retal foi inoculado em tubos contendo caldo Todd-Hewitt com posterior subcultura em ágar sangue. A
identificação do EGB foi realizada através de testes presuntivos, confirmadas por teste sorológico e avaliado seu perfil de
sensibilidade. Pesquisou-se ocorrência de transmissão materno-fetal do EGB nas gestantes colonizadas. A prevalência de
colonização foi de 11 ,11%. Todas as cepas foram sensíveis à penicilina, ampicilina e vancomicina. Duas cepas (50%)
foram intermediárias à clindamicina e uma (25%) intermediária à eritromicina. Um recém-nascido de mãe colonizada
teve infecção neonatal de início precoce por EGB. Confirma-se a importância da pesquisa de colonização por EGB em
todas as gestantes entre 35ª e 37ª semana de gestação e uso de quimioprofilaxia intraparto nas gestantes colonizadas.
Descritores: Streptococcus agalactiae; Prevalência; Gestantes; Recém-nascido; Testes de Sensibilidade Microbiana.
INTRODUCTION
Streptococcus agalactiae or group B
streptococcus (GBS) is a normal inhabitant of the
gastrointestinal tract and may colonize the vagina
chronically or intermittently in about a third ofwomen.
The colonized pregnant women are usually
asymptomatic, but the GBS is responsible for 2-4% of
urinary infections during pregnancy.1 In pregnancy and
puerperium this colonization may compromise the
amnion, endometrium and abdominal wall, leading to
abortion and prematurity.2,3
Around 50 to 75% of neonates exposed to GBS
intravaginal become colonized and 1 to 2% of all
newborns of positive mothers will develop early-onset
invasive disease.4-6 Neonatal invasive infections by
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S. agalactiae are more common than other well-known
neonatal diseases such as rubella, syphilis and spina
bifida.1
Systemic infection by GBS has two
manifestations in the newborn: a) the early-onset
disease, which derives from vertical transmission or
through the aspiration ofcontaminated amniotic fluid4,7,
and it manifests itself in the first 24 hours of life,
causing pneumonia , sepsis, and, less commonly,
meningitis1,8,9 and b) the late-onset disease, which
manifests itself from 7 days to 12 weeks of life and it
may be of maternal or nosocomial origin and
characterized mainly by meningitis.1 Neurological
sequelae occur in approximately 30-50% ofmeningitis
survivors.4,9
The presence ofmaternal colonization prevalence
between 15 and 25% places Brazil in a level ofconcern
when considering the possibility that high rates ofearly-
onset neonatal infection are occurring without being
identified,10 as there are no manuals or technical
recommendations on the theme in the country.11
Our objective was to assess the prevalence of
vaginal and/or rectal colonization by S. agalactiae and
its susceptibility to antimicrobials in pregnant women
from 35 to 37 weeks of gestation who were treated at
University Hospital of Santa Maria (HUSM) in Santa
Maria, RS.
MATERIALAND METHODS
This is a cross-sectional, prospective and
retrospective, active and passive study in which we
assessed the colonization prevalence and susceptibility
ofGBS in 36 pregnant women treated at the Obstetric
Center (OC) of HUSM from June to December
2009. The study included women from 35 to 37 weeks
of gestation + 6 days with intact membranes. The
exclusion criteria were the presence ofvaginitis, AIDS,
HIV positive andwho received antimicrobial therapy in
the last 15 days.
The participants were informed about the
objectives and procedures of the study and signed a
consent form. The study was approved by the Ethics
Committee on Human Beings ofthe Federal University
of Santa Maria (UFSM) in May 2008, under number
0235.0.243.000-08.
The sample collection was performed by the team
ofHUSM OC, following the guidelines of the Centers
for Disease Control and Prevention (CDC).1 With
sterile swabs samples were collected vaginal (vaginal
opening) and a rectal examination (insertion of the
swab through anal sphincter) and inoculated separately
into two test tubes containing Todd-Hewitt selective
broth medium plus gentamicin (8µg/mL) and nalidixic
acid (15µg/mL). All samples were properly identified
and sent to the Laboratory of Bacteriology, Building
26, Room 1201, Center for Health Sciences,
Department of Clinical and Toxicological Analysis of
UFSM to be processed.
The selective broths were incubated in a 5% CO2
for 18 to 24 hours at 35±2º C and subcultured on blood
agar under the same conditions of incubation. After 24
hours, the plates were identified as suggestive of
S. agalactiae by colonial morphology (gray, surrounded
by a discrete halo ofhemolysis total, non-hemolytic or
alpha-hemolytic), Gram stain (gram positive), ability to
produce catalase (catalase negative), bile esculin
(negative) and CAMP factor (positive). For
confirmation, serology was performed using the latex
agglutination with PASTOREXTM STREP kit (Bio-
Rad).
The antimicrobial susceptibility of isolates was
performed using disc diffusion method, as
recommended by the Clinical and Laboratory
Standards Institute (CLSI, 2010).12 We tested the
antibiotic ampicillin, cefotaxime, clindamycin,
erythromycin, levofloxacin, penicillin and vancomycin.
For the research on the inducible resistance to
clindamycin to be made, erythromycin and
clindamycin disks were placed at a distance of 20mm
disc to disc (Test D). The positivity of this test is
viewed by the flattening ofthe halo ofclindamycin.
When there was a confirmation of maternal
colonization by S. agalactiae, a passive assessment was
made with the records in order to detect the occurrence
of early-onset or late-onset neonatal infection in these
women’s newborns through positive blood culture
and/or cerebrospinal fluid (CSF) and the evolution of
this patient was assessed.
RESULTS
From 36 women included in the study, four of
them had vaginal and/or rectal culture GBS-positive,
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resulting in a prevalence of 11.11%. Tests for the
presumptive identification of S. agalactiae in these
women are depicted in Table 1.
The antimicrobials tested are listed in Table 2 with
the group which they belong, according to CLSI 2010:
Group A (first choice, tested and reported in the
routine), group B (first choice, tested and reported
selectively, especially important agents in nosocomial
infections), group C (additional and reported
selectively, alternative agents when there are strains
resistant to multiple primary drugs). All of them
showedD test negative.
Pregnant Woman (nº) Catalase Bile esculin Hemolysis CAMP Serology
5 - - β - +
7 - - β - +
34 - - β + +
+35 - - y -
(+) positive; (-) negative
TABLE 1 - Tests results for S. agalactiae identification in colonized pregnant women
Pregnant woman (nº) AMP (A) CTX (B) CLI (A) ERI (A) LEV (C) VAN (B)
5 S S I I S S
7 S S I S S S
34 S S S S S S
35 S S S S S
PEN (A)
S
S
S
S S
AMP = ampicillin, CTX = cefotaxime, CLI = clindamycin, ERI = erythromycin,
LEV = levofloxacin, PEN = penicillin, VAN = vancomycin.
S = Susceptible, I = Intermediate.
In a newborn whose mother was colonized with
GBS the occurrence of early-onset neonatal infection
was observed. The baby was born with prematurity and
prolonged delivery, he needed resuscitation and he was
transferred to ICU. He was diagnosed with meningitis
caused by S.agalactiae, isolated from blood culture and
CSF, and he was treated with ampicillin (1/40 16mL IV
12/12h) and gentamicin (40/20 5.5 mL IV 24/24h). He
was discharged after 18 days.
DISCUSSION
Among the tests performed according to
conventional methodology for identification of GBS,
the CAMP test is one ofthe most sensitive.13 This test is
based on production of a diffusible hemolysin by most
strains of GBS, which together with other hemolysin
produced by Staphylococcus aureus ?-hemolytic strains
(ATCC 25923) causes complete lysis ofred blood cells
from blood agar plate and produces a characteristic
zone of hemolysis in the form of arrowheads, called
factor CAMP.6,13 In our tests only one sample was
positive for the presence of CAMP factor,
demonstrating a low sensitivity for identifying GBS
isolated in this study. Other identification tests had
results whichwere consistent with the literature.13
The prevalence of maternal GBS colonization
varies from 5 to 40% concerning some factors such as
the gestation period in which cultures are performed,
the collection site, the bacteriological methods used to
detect GBS and the origin and characteristics of the
population studied.1,2,10
In this study we chose to search GBS both
vaginal and rectal sites, as there are reports that the
colonization rate increases from 5 to 25% when the
TABLE 2 - Susceptibility to antimicrobials offour pregnant women with culture vaginal and/or rectal GBS-positive
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sample is collected in more than one site.1 Simões et
al. (2007) demonstrated that 56.5% of colonized
pregnant women would not be identified if there was
only the rectal sample, and in case of only vaginal
sample, in 20% ofwomen this colonization would not
be diagnosed.14
Since 2002, the CDC emphasizes the universal
search for GBS colonization rather than the protocol
based on risk factors, once studies showed that this
strategy was more effective to define the use of
intrapartum chemoprophylaxis, especially taking into
account that many colonized pregnant women did not
have risk factors for newborn infection.1,5,14,15
In this context, studies that evaluate the rate of
GBS colonization have been performed worldwide and
the prevalence rates are variable: 8.6% in Mexico in
1999;16 10.6% in Turkey in 2000,17 9.1% in Iran in
2003,5 7.6% inArgentina between 2004 and 2006.18
In Brazil, these rates have become even higher. In
a study conducted between 2002 and 2003, in a public
maternity hospital in Londrina – Paraná, a prevalence
of 14.9% was found.2 Another one conducted in the
same period in Florianopolis - Santa Catarina presented
a GBS colonization of 21.6%.19 In Rio de Janeiro
prevalence rates of 19.2% were found from 2003 to
2004.20 A study accomplished at the Center for Integral
Attention to Women's Health at the University of
Campinas in 2003 and 2004 found the rate ofmaternal
GBS colonization of 27.6%.6 In São Luis - Maranhão,
the prevalence was 20.4% from 2005 to 2006.10 The
present study showed a colonization rate of slightly
lower than the national ones (11.11%).
The currently recommended prophylaxis for the
prevention ofneonatal disease is the use of intrapartum
antibiotics only for women colonized by GBS. CDC
indicates penicillin as the first choice drug for
intrapartum antibiotic prophylaxis (5 million U IV then
2.5 million U 4/4h until delivery) and treatment of
neonatal infection by S. agalactiae (200 to 500,000
U/kg/day) in association with gentamicin.1,21,22
Ampicillin can be used alternatively. Erythromycin and
clindamycin are the drugs of choice for prophylaxis in
women colonized by GBS who are allergic to
penicillin.1
Althoughmost strains are susceptible to penicillin,
14,15,20,23,24 the increased use of erythromycin and
clindamycin in patients allergic to penicillin or for the
prevention and treatment ofother infections, has shown
growth rates ofGBS resistance to these antimicrobial
agents inmany countries, including Brazil.15, 20
A study made from 1994 to 1999 in Rio de
Janeiro found in colonized women 5.4% and 1.1% of
GBS resistance to erythromycin and clindamycin,
respectively.25 But in recent years the GBS resistance
rates to these antibiotics have steadily been increasing
in colonized women. In 2003-2004 Borger et al. found
9.4% resistance of S. agalactiae to erythromycin and
6.2% to clindamycin.20 Costa et al., in 2005-2006,
found rates of 23.6 and 25.4%10 and Castellano-Filho
et al., in 2007-2008, found 22.7 % and 50% resistance
to erythromycin and clindamycin, respectively.15
In relation to susceptibility of four pregnant
women colonized by GBS in the present study, we
found no resistance to the tested antimicrobials. All
pregnant women were susceptible to penicillin and
ampicillin, suggesting that intrapartum antibiotic
prophylaxis of first choice in patients who are not
allergic would have satisfactory results in our
hospital. Two pregnant women presented an
intermediate profile to clindamycin and one did the
same to erythromycin. This reflects a reduction ofGBS
susceptibility to these antibiotics and intensifies
attention to its use, especially in patients who are
allergic to penicillin, since for the latter ones the usual
doses of these antibiotics may be ineffective in
intrapartum antibiotic prophylaxis.
Even with the CDC recommendations, many
cases ofearly-onset neonatal infection still occur in our
midst. In Porto Alegre - Rio Grande do Sul was found
an incidence of early-onset neonatal GBS infection of
1/1000 born alive26 while in Campinas - Sao Paulo, a
higher incidence of10.3/1000 born alive was found.6
The presence of one case of early-onset neonatal
infection among four colonized pregnant women
reflects the occurrence of GBS maternal-fetal
transmission in our center. This reinforces the necessity
of implementing a program for prevention of GBS
infection including the detection ofcolonization during
the 35-37 weeks ofpregnancy as a fundamental test of
prenatal care, besides that obstetricians should join this
case due to its great importance.
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CONCLUSION
The high frequency of GBS colonization, the
increase in resistance to certain antibiotics
recommended by the CDC and the occurrence of
neonatal GBS infection in our population underscores
the importance of the survey of S. agalactiae
colonization and their antimicrobial susceptibility
during 35-37 weeks ofgestation. This leads to a rational
choice ofantimicrobial agent to be used in the antibiotic
prophylaxis of pregnant women known to be
colonized, it also reduces the unnecessary use of
intrapartum antibiotic prophylaxis when it is based only
on risk factors, in addition preventing GBS maternal-
fetal transmission.
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